000 03879nam a22004935i 4500
001 vtls000544903
003 RU-ToGU
005 20210922083124.0
007 cr nn 008mamaa
008 160915s2014 gw | s |||| 0|eng d
020 _a9783642451959
_9978-3-642-45195-9
024 7 _a10.1007/978-3-642-45195-9
_2doi
035 _ato000544903
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
245 1 0 _aProstate Cancer Prevention
_helectronic resource
_cedited by Jack Cuzick, Mangesh A. Thorat.
260 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg :
_bImprint: Springer,
_c2014.
300 _aVIII, 169 p. 11 illus., 4 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aRecent Results in Cancer Research,
_x0080-0015 ;
_v202
505 0 _aBiology and natural history of prostate cancer -- Nutrition and prostate cancer -- Prostate cancer chemoprevention -- Lifestyle and dietary factors -- GWAS in prostate cancer predisposition and application to screening and prevention -- Risk prediction biomarkers – CCP -- Risk prediction biomarkers - TMPRSS2-ERG -- Risk prediction biomarkers – PCA3 -- Risk adapted chemoprevention for PCa -- Outlook for 5α reductase inhibitors in prostate cancer prevention -- Prostate cancer chemoprevention: Aspirin -- Prostate cancer chemoprevention: DFMO -- Prostate cancer chemoprevention: Lycopene -- Distinguishing aggressive from indolent prostate cancer -- Prognosis and Management of low grade disease - Management of Gleason 6 -- Prostate cancer prevention: Policy & Research implications.
520 _aProstate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely.   A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.
650 0 _amedicine.
_9566220
650 0 _aOncology.
_9303086
650 0 _aUrology.
_9308137
650 1 4 _aMedicine & Public Health.
_9566221
650 2 4 _aOncology.
_9303086
650 2 4 _aUrology/Andrology.
_9308138
650 2 4 _aCancer Research.
_9566267
700 1 _aCuzick, Jack.
_eeditor.
_9452638
700 1 _aThorat, Mangesh A.
_eeditor.
_9452639
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
830 0 _aRecent Results in Cancer Research,
_9316621
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-45195-9
912 _aZDB-2-SME
999 _c402548